NEW YORK (GenomeWeb) – Invivoscribe has received CE marking and launched next-generation sequencing-based assays for detecting clonality in hematological malignancies.

The LymphoTrack Dx TRG assay assesses T-cell receptor gamma rearrangements, while the LymphoTrack DX IGH FR1 assay assesses immunoglobulin heavy chain gene rearrangements.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.